Le Lézard
Classified in: Health, Science and technology
Subjects: Webcast, Advisory

QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter of 2022.

Press release date / time: Wednesday, July 27, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, July 28, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.

Three options for joining the conference call

Register for call back connection


Click here:

Connect Me


Service available 15 minutes before call start

Dial-in by phone



+1 646 828 8075 (U.S.)

+44 (0)330 165 4012 (UK)

+49 (0)69 22222 5197 (GER)


To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.


Conference ID: 3332305


Access the audio webcast


Click here:

Access Webcast

A conference call replay will be available by using the following link:

Contact: IR@qiagen.com


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

These press releases may also interest you

at 10:45
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") , a clinical stage immunotherapy company, is pleased to announce the closing of its previously announced marketed underwritten public offering of units (the "Units") of the Company in Canada...

at 10:30
In March 2020, when COVID-19 was beginning to shut down Canadian society, shelves in stores across the country quickly went empty. Businesses found themselves struggling to keep up with demand....

at 10:30
Scanslated, Inc., a radiologist-led healthcare technology company, today announced that it has partnered with Duke Health to deliver its patient-centered, interactive radiology reporting service to patients at Duke's three hospitals and 14 outpatient...

at 10:30
atria health, a value-based provider of technology and administrative support services to cardiovascular care physicians, today announced its formal launch. The physician-owned company empowers community cardiologists through a highly integrated,...

at 10:26
August officially marks Hair Loss Awareness Month (HLAM) and is advantageous for announcing the most progressive and effective new treatments and technology for the estimated 80 million men and women that are suffering from hair loss (statistics...

at 10:20
Enable Injections, Inc. ("Enable"), a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D. to the company's Board of Directors,...

News published on 7 july 2022 at 06:05 and distributed by: